Clinical Trial Update: A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

View source ↗

Summary

A clinical trial registry entry for Janssen's prospective compliance registry in metastatic castration-resistant prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Prostatic Neoplasms | Status: WITHDRAWN